NasdaqGS - Delayed Quote USD
Allakos Inc. (ALLK)
At close: November 6 at 4:00 PM EST
After hours: November 6 at 5:11 PM EST
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Robert Alexander Ph.D. | CEO & Director | 1.5M | -- | 1970 |
| Dr. Adam L. Tomasi Ph.D. | President | 1.15M | -- | 1970 |
| Mr. Baird Radford III | Chief Financial Officer | 731.35k | -- | 1970 |
| Ms. Mary Cromwell Ph.D. | Chief Technical Officer | -- | -- | -- |
| Dr. Chin Lee M.D., M.P.H. | Chief Medical Officer | -- | -- | 1970 |
| Mr. Alan Chang | Director of Medical Affairs & Data Analytics | -- | -- | -- |
Allakos Inc.
825 Industrial Road
Suite 500
San Carlos, CA 94070
United States
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 131
Description
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Corporate Governance
Allakos Inc.’s ISS Governance QualityScore as of November 1, 2024 is 10. The pillar scores are Audit: 6; Board: 10; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 6, 2024 at 9:02 PM UTC
Allakos Inc. Earnings Date
Recent Events
Related Tickers
XLO Xilio Therapeutics, Inc.
1.2900
-1.53%
QNCX Quince Therapeutics, Inc.
1.4600
+4.29%
NUVB Nuvation Bio Inc.
2.5400
+9.48%
EPIX ESSA Pharma Inc.
1.7100
+0.59%
LYEL Lyell Immunopharma, Inc.
1.4800
+19.35%
ZNTL Zentalis Pharmaceuticals, Inc.
3.8400
+1.59%
SYRS Syros Pharmaceuticals, Inc.
2.4500
-3.16%
ANAB AnaptysBio, Inc.
22.21
+11.72%
VRPX Virpax Pharmaceuticals, Inc.
0.7125
+2.95%
ACLX Arcellx, Inc.
92.98
+6.73%